Group 1 - The Annual General and Special Meeting of EverGen Infrastructure Corp. is being held both in person and via video conference [2][4] - The meeting is chaired by the CEO of EverGen, Chase Edgelow, who also introduced the directors and officers present [1][2] - A brief corporate update will follow the formal meeting, with a more comprehensive update planned for the coming weeks [3] Group 2 - The meeting will include a report from the scrutineer on the shareholders present, both in person and by proxy, as well as the results of any ballots or polls [4]

Core Insights - Evogene Ltd. is focusing on computational chemistry and the generative design of small molecules for pharmaceuticals and agriculture, with a strategic emphasis on its AI-driven platform, ChemPass AI [1] Financial Performance - On November 20, 2025, Evogene reported earnings per share of $0.44, exceeding the estimated loss of $0.41 per share [2][5] - The company generated revenue of $312,000, which was below the estimated $650,000, indicating challenges in meeting market expectations [2][5] Valuation Metrics - The price-to-sales ratio is approximately 1.40, indicating that investors are willing to pay $1.40 for every dollar of sales, reflecting confidence in Evogene's potential [3] - The enterprise value to sales ratio stands at about 2.04, showing the company's valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is around -0.78, suggesting difficulties in generating positive cash flow from operations [3] Liquidity and Debt Position - Evogene's debt-to-equity ratio is approximately -3.57, indicating more liabilities than equity [4] - The current ratio is about 1.89, suggesting a relatively healthy liquidity position that allows the company to cover its short-term obligations [4]

Core Insights - EverGen Infrastructure Corp. reported its Q3 2025 financial results, highlighting a record in RNG production and ongoing optimization efforts across its facilities [2][5]. Financial Performance - Revenue for Q3 2025 was CAD 2.81 million, a decrease of 22% from CAD 3.60 million in Q3 2024 [4]. - The net loss increased to CAD 1.11 million in Q3 2025 from CAD 0.47 million in Q3 2024, marking a 134% rise [4][8]. - Adjusted EBITDA for Q3 2025 was CAD 0.47 million, down 52% from CAD 0.98 million in the same period last year [4][9]. - Total assets decreased by 16% to CAD 76.54 million from CAD 91.64 million year-over-year [4]. Operational Highlights - RNG production reached a new quarterly record, with total production of 51,770 gigajoules in Q3 2025, an increase of 27% compared to 40,674 gigajoules in Q3 2024 [4][7]. - The FVB facility set a new monthly RNG production record of over 13,000 gigajoules in September 2025 [3][5]. - Incoming organic feedstock decreased by 40% to 15,310 tonnes compared to 25,555 tonnes in Q3 2024 [4]. Strategic Developments - The PCR RNG Expansion project received regulatory support from Abbotsford City Council in July 2025, marking a key milestone [5][10]. - The company is advancing refinancing efforts, targeting a CAD 13 million debt facility to close in Q4 2025, along with an additional private placement of up to CAD 2 million [11]

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from $4 million in the same period last year, primarily due to lower revenue from AgPlenus activity [9][31] - Total operating loss for the nine months of 2025 was approximately $8.8 million, significantly reduced from approximately $15.3 million in the same period of 2024, mainly due to decreased operating expenses [10][35] - The net loss for the nine months of 2025 was approximately $2.5 million, compared to approximately $18 million in the same period last year, reflecting a $15.5 million decrease primarily due to reduced operating expenses and income from discontinued operations [37][38] Business Line Data and Key Metrics Changes - Lavie Bio's financial results are presented as a single line item in Evogene's consolidated P&L statement, reflecting the sale of the majority of its activities to ICL, which generated income of approximately $7.9 million in Q3 2025 [9][29] - Research and development expenses for the nine months of 2025 were approximately $6.2 million, down from $9.8 million in the same period of 2024, attributed to reduced R&D expenses in Biomica and the cessation of Canonic's operations [31][32] - Sales and marketing expenses for the nine months of 2025 totaled approximately $1.2 million, a decrease from approximately $1.6 million in the same period last year, mainly due to personnel cost reductions [10][32] Market Data and Key Metrics Changes - The global agricultural market was valued at $79 billion in 2024, with significant opportunities for new product development in herbicides, insecticides, and fungicides [21] - The pharmaceutical market for small molecule-based drugs is valued at approximately $780 billion, representing nearly 60% of the global pharmaceutical market [24] Company Strategy and Development Direction - The company is transitioning to focus on computational chemistry, particularly in the generative design of small molecules for the pharmaceutical and agriculture industries [7][27] - The strategy includes leveraging the proprietary generative AI tech engine, Campus AI, to design novel small molecules that meet multiple parameters for commercial success [18][27] - The company aims to strengthen collaborations with leading global companies in both the agriculture and pharmaceutical sectors to drive innovation and product development [20][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increased interest in AI-driven drug discovery following recent partnerships in the industry, indicating a positive outlook for Evogene's technology [41][42] - The company expects to announce additional collaborations with biotech companies and academic institutions in the near future, aiming to enhance its market position [46][50] - Management expressed confidence in the potential for success in the pharmaceutical sector, emphasizing the unique capabilities of their team and technology [56][57] Other Important Information - The company completed a cost reduction plan by the end of Q2 2025, which is reflected in the reduced operating expenses in Q3 2025 [8][29] - The cash balance as of September 30, 2025, was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets [10][30] Q&A Session Summary Question: Has the levels of interest in AI champs increased post the recent NVIDIA Eli Lilly AI drug discovery partnerships? - Management noted that the announcement increased interest in AI-related companies in the pharma industry, and Evogene has seen growing interest in its technology [41][42] Question: How close are you to unlocking partners with AI champs? - Management indicated an increase in potential candidates for collaboration and expects to announce new partnerships with biotech companies early next year [45][46] Question: What is the IR strategy going forward? - Management confirmed plans to initiate roadshows and participate in conferences to enhance awareness of the company's new strategy and technology [47][49] Question: Could you highlight upcoming catalysts over the coming 6-12 months? - Management outlined expectations for new collaborations in both the pharma and ag divisions, as well as potential announcements regarding partnerships with major tech companies [50][51] Question: What type of revenue level can we expect for customer seeds in Q4 and for 2026? - Management refrained from disclosing specific revenue levels but mentioned ongoing discussions with strategic companies that could significantly impact future revenue [52][53] Question: How excited are you about AI champs compared to all your other times at Evogene? - Management expressed optimism about the focus on the pharma industry and the potential for significant financial rewards from successful collaborations [54][56]

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from approximately $4 million in the same period last year, primarily due to lower revenue from AgPlenus activity [9][31] - Total operating loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of the previous year, mainly due to reduced operating expenses [10][35] - The net loss for the nine months of 2025 was approximately $2.5 million compared to approximately $18 million in the same period last year, reflecting a $15.5 million decrease primarily due to decreased operating expenses and income from discontinued operations [37][38] Business Line Data and Key Metrics Changes - The financial results of Lavie Bio, Evogene's subsidiary, are presented as a single line item in the consolidated P&L statement for 2025, reflecting the sale of the majority of its activities to ICL [8][29] - Research and development expenses for the nine months of 2025 were approximately $6.2 million, a decrease of approximately $3.6 million compared to $9.8 million in the nine months of 2024, primarily due to reduced R&D expenses in Biomica and the cessation of Canonic's operations [31][32] - Sales and marketing expenses for the nine months of 2025 were approximately $1.2 million, a decrease of approximately $400,000 compared to approximately $1.6 million in the same period last year, mainly due to personnel cost reductions [10][32] Market Data and Key Metrics Changes - The global agricultural market was valued at $79 billion in 2024, with significant opportunities for new product development in herbicides, insecticides, and fungicides [21] - The global pharmaceutical market for small molecule-based drugs is valued at approximately $780 billion, representing nearly 60% of the market [23] Company Strategy and Development Direction - The company is transitioning to focus on computational chemistry and generative design of small molecules for the pharmaceutical and agriculture industries [6][7] - The strategy includes leveraging the proprietary generative AI tech engine, Campus AI, to design novel small molecules that meet multiple parameters for commercial success [12][18] - The company aims to strengthen collaborations with leading global companies in both agriculture and pharmaceuticals to drive innovation and product development [28][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increased interest in AI-driven drug discovery following recent partnerships in the industry, indicating a positive outlook for Evogene's technology [39][40] - The company expects to announce additional collaborations in the pharma division and expand existing partnerships in agriculture, which are anticipated to generate cash inflows [47][48] Other Important Information - The company completed a cost reduction plan, which is reflected in the reduced operating expenses for the third quarter of 2025 [8][29] - The cash balance as of September 30, 2025, was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets [10][30] Q&A Session Summary Question: Has the levels of interest in AI champs increased post the recent NVIDIA Eli Lilly AI drug discovery partnerships? - Management noted that the announcement increased interest in AI-related activities in the pharma industry, and they have seen growing interest in their technology [39][40] Question: How close are you to unlocking partners with AI champs? - Management indicated that interest has increased significantly, and they expect to announce new collaborations with biotech companies early next year [43][44] Question: What is the IR strategy going forward? - Management confirmed that they will focus on presenting the new company strategy and will initiate roadshows and participate in conferences to increase visibility [45][46] Question: Could you highlight upcoming catalysts over the coming 6-12 months? - Management expects to announce new collaborations in both the pharma and ag divisions, as well as additional partnerships with major tech companies [47] Question: What type of revenue level can we expect for customer seeds in Q4 and for 2026? - Management refrained from disclosing specific revenue levels but mentioned ongoing discussions with strategic companies that could significantly impact future revenue [48] Question: How excited are you about AI champs compared to all your other times at Evogene? - Management expressed optimism about the focus on the pharma industry, highlighting the unique expertise of their team and the potential for significant financial rewards [49][50]

Core Insights - Casterra Ag Ltd. and Fantini Italia S.R.L. have announced a strategic collaboration aimed at large-scale commercial castor cultivation through advanced mechanization technologies, addressing the rising global demand for castor oil used in biofuels and bio-based industrial products [1][2][4] Industry Overview - The global castor oil and derivatives market is valued at approximately USD 2.4 billion and is projected to reach USD 3.09 billion by 2030, growing at a CAGR of 5.20% [3] Company Collaboration - The partnership between Casterra and Fantini focuses on integrating high-yield castor varieties with advanced harvesting and threshing technologies, aiming to modernize castor farming and support industrial-scale production [4][5] - Casterra's high-yield castor varieties are designed for industrial-scale cultivation and are compatible with Fantini's precision harvesting technologies, facilitating tailored solutions for various geographical markets [4][5] Environmental Commitment - Both companies emphasize their commitment to sustainability, with Fantini's machinery reportedly reducing carbon footprint by about two-thirds compared to conventional solutions [5][10]

Core Insights - Evogene Ltd. will release its financial results for Q3 2025 on November 20, 2025, followed by a conference call at 9:00 AM ET to discuss the results [1][2]. Company Overview - Evogene Ltd. is a pioneering company in computational chemistry, focusing on the generative design of small molecules for the pharmaceutical and agricultural sectors [3]. - The company's technology is centered around ChemPass AI, a proprietary generative AI engine that enhances the design of novel, highly potent small molecules, optimizing multiple critical parameters [3]. - This platform aims to improve success rates while reducing development time and costs [3]. Strategic Focus - Evogene is dedicated to creating breakthrough products through strategic partnerships and internal product development, emphasizing the integration of scientific innovation with real-world industry needs, termed "Real-World Innovation" [4].

Core Insights - EverGen Infrastructure Corp. provided updates on its operations in renewable natural gas (RNG) and organic waste processing facilities, highlighting strong production metrics and strategic initiatives aimed at enhancing revenue and profitability [1][2][3] Operations Update - In July 2025, EverGen's Fraser Valley Biogas and GrowTEC facilities produced approximately 16,000 gigajoules (GJs) (~520 GJ/d), while in August 2025, production increased to over 17,000 GJs (~550 GJ/d), indicating stable growth in core RNG assets [2] - The company focused on optimization initiatives at its organic waste processing facilities, including screening finished compost and reducing inventory [2] - The PCR RNG Expansion project achieved a key regulatory milestone with support from Abbotsford City Council, and a legacy organics processing contract with the City of Coquitlam was terminated [2] Strategic Initiatives - EverGen aims to attract higher-value organic feedstock through process improvements and RNG expansion, which are expected to support increased revenue in 2026 and long-term profitability [2][3] - The company is committed to optimizing its RNG and organics processing platform while delivering strong operational performance and driving sustainable growth [3] Company Overview - EverGen Infrastructure Corp. is recognized as Canada's Renewable Natural Gas Infrastructure Platform, focusing on combating climate change and contributing to a sustainable future [3] - The company is an established independent renewable energy producer, acquiring, developing, building, owning, and operating a portfolio of RNG and waste-to-energy projects, with growth expected across North America [3]

Core Insights - Evogene Ltd. will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025 [1] - The presentation will focus on the strategic emphasis on ChemPass AI, a proprietary generative AI technology for small molecule discovery and optimization in pharmaceuticals and agriculture [2] - One-on-one meetings will be available for interested investors and companies during the conference [3] Company Overview - Evogene Ltd. is an AI-driven discovery and development company specializing in novel small molecules for the pharmaceutical and agricultural chemical industries [4] - The company's innovation is centered around ChemPass AI, designed to create highly potent small molecules while addressing challenges in discovery and optimization [4] - Evogene aims to enhance the probability of success and reduce development costs through its technology, which supports both strategic partnerships and internal product pipelines [4]

Financial Data and Key Metrics Changes - Total revenues for 2025 were approximately $3.2 million, an increase from $2.3 million in 2024, primarily driven by strong seed sales from the subsidiary Castera [9][26] - Research and development expenses for 2025 were approximately $4.8 million, down from $6.5 million in the same period last year, due to reduced R&D activities at Biomica and the discontinuation of operations at Canonic [10][27] - Total operating expenses for 2025 were approximately $7.7 million, significantly decreased from $11.1 million in the same period last year, attributed to reduced activity levels in subsidiaries [11][29] - The net loss for 2025 was approximately $7.7 million, compared to $9.8 million in the same period last year, reflecting decreased operating expenses and increased financing income [32] Business Line Data and Key Metrics Changes - Castera, the subsidiary responsible for seed sales, was the primary contributor to revenue growth, with revenues recognized for seed sales in 2025 [9][26] - Biomica is focused on completing its clinical trial expected in early 2026 and securing partners for its development programs, holding approximately $4 million in cash [17][21] - Laviv Bio's activities were largely sold to ICL, with a total consideration of $15.25 million, enhancing cash flow for Evogene [14] Market Data and Key Metrics Changes - The company is undergoing a strategic shift to maximize the value of Campus AI, focusing on AI-driven discovery and optimization in pharmaceuticals and agriculture [12][19] - The collaboration with Tel Aviv University aims to develop small molecule therapeutics targeting diseases caused by metabolite accumulation, leveraging Campus AI [13] Company Strategy and Development Direction - The strategic priorities include strengthening Campus AI, expanding collaborations in small molecule drug discovery, and streamlining operational expenses [12][19] - The company plans to establish a dedicated business development arm to accelerate growth in the pharmaceutical vertical and maintain strategic collaborations in agriculture [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new strategic direction and the potential for increased investor interest as new collaborations are announced [40] - The company expects continued reductions in operating expenses in the third and fourth quarters of 2025 [42] Other Important Information - Evogene raised $4.4 million through an at-the-market facility, enhancing its financial position and providing an operational runway of approximately 18 months [18] - The company is focusing on operational discipline and long-term value creation, with plans to present its updated corporate strategy at industry conferences [23] Q&A Session Summary Question: How much caster seed inventory do you have today, both finished and expected to be finished after the harvest? - The company has a few hundred tons of castor seed ready for sale and plans to utilize its seeds for cultivation to sell grain to partners [35][36] Question: What steps need to occur before you can announce a castor oil business? - The company is currently focused on grain cultivation and selling grain to partners, with existing crushing oil factories eager for castor grain [38] Question: The stock is still low. When will it start going up? - Management indicated that they cannot control the stock market but are finalizing a new company presentation and plan to announce new collaborations that could positively impact stock value [39][40] Question: How representative are operating expenses in Q2 2025 for going forward operations? - Management confirmed that all cost reductions are fully reflected in the numbers, with expectations for continued expense declines [42] Question: What was revenue in Q2 2025? How should we think about peak sales given recent results? - The revenue in Q2 2025 was primarily from Castera, with expectations for future sales growth as the company engages with multiple partners [43][44] Question: For Campus AI platform, what catalyst milestones should we expect in the next twelve to eighteen months? - The company anticipates announcements of new collaborations and breakthroughs in technology development as key milestones [46][49]